Is Trevi Therapeutics Inc (NASDAQ: TRVI) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

Stocks Info

TRVI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Trevi Therapeutics Inc is $396.79M. A total of 1.11 million shares were traded on the day, compared to an average of 1.92M shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, TRVI has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.

In the most recent transaction, GOOD JENNIFER L sold 4,219 shares of TRVI for 3.03 per share on Sep 06 ’24. After the transaction, the President & CEO now owns 213,313 company shares. In a previous transaction on Sep 09 ’24, GOOD JENNIFER L sold 1,840 shares at 3.04 per share. TRVI shares that President & CEO owns now total 213,313.

Among the insiders who sold shares, GOOD JENNIFER L disposed of 40,277 shares on Sep 05 ’24 at a per-share price of $3.11. This resulted in the President & CEO holding 213,313 shares of TRVI after the transaction. In another insider transaction, GOOD JENNIFER L sold 10,981 shares at $3.02 per share on Sep 04 ’24. Company shares held by the President & CEO now total 213,313.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for TRVI in the last 3 months, the mean price target is $10.41 with high estimates of $21.00 and low estimates of $7.00. In terms of 52-week highs and lows, TRVI has a high of $5.05 and a low of $2.30.

As of this writing, TRVI has an earnings estimate of -$0.11 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.11 per share and a lower estimate of -$0.13.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. TRVI’s latest balance sheet shows that the firm has $36.83M in Cash & Short Term Investments as of fiscal 2021. There were $14.63M in debt and $12.72M in liabilities at the time. Its Book Value Per Share was $0.78, while its Total Shareholder’s Equity was $17.07M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TRVI is Buy with a score of 4.78.

Most Popular

Related Posts